share_log

Piper Sandler Maintains Overweight on Altimmune, Maintains $25 Price Target

Benzinga ·  Jun 22 01:51

Piper Sandler analyst Yasmeen Rahimi maintains Altimmune (NASDAQ:ALT) with a Overweight and maintains $25 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment